Conflict of Interest
Alentis
ONCOLOGY
Kimberly Perez was a one-time advisory board member for Lantheus and QED/Helsinn. James M. Cleary receives research funding to his institution from Merus, Roche, and Bristol Myers Squibb; he receives research support from Merck, AstraZeneca, Esperas Pharma, Bayer, Tesaro, Arcus Biosciences, and Apexigen; he has also received honoraria for being on the advisory boards of Syros Pharmaceuticals, Incyte, and Blueprint Medicines. Lawrence Blaszkowsky reports that spouse has equity in Pfizer. Peter Enzinger is a consultant for ALX Oncology, Arcus Bioscience, Astellas, AstraZeneca, Blueprint Medicines, Chimeric Therapeutics, Celgene, Coherus, Daiichi-Sankyo, Five Prime, Ideaya, Istari, Legend, Lilly, Loxo, Merk, Novartis, Ono, Servier, Taiho, Takeda, Turning Point Therapeutics, Xencor, and Zymeworks. Marios Giannakis reported research funding from Merck, Servier, and Janssen. Lipika Goyal serves on the Scientific Advisory Committee for Alentis Therapeutics AG, Black Diamond, Exelixis, Genentech, H3Biomedicine, Kinnate, Incyte Corporation, QED Therapeutics, Merck, Servier, Sirtex Medical Ltd, Surface Oncology, Taiho Oncology Inc., TranstheraBio; on the DSMC for AstraZeneca; and as a consultant for Alentis Therapeutics, Genentech, Exelixis, Incyte Corporation, QED Therapeutics, Servier, Sirtex Medical Ltd, Taiho Oncology Inc., TranstheraBio, and Tyra Biosciences. Jeffrey A. Meyerhardt has served as an advisor/consultant to Merck Pharmaceutical and COTA Healthcare. Douglas Rubinson serves on the Scientific Advisory Board for AxialTx Consulting, Boston Scientific, and Instylla. Matthew B. Yurgelun has received research funding from Janssen Pharmaceuticals and fees for peer review services from UpToDate. Victoria Germon reports that spouse is an employee of Pfizer. Srivatsan Raghavan holds equity in Amgen. Andrew J. Aguirre reports consulting for Arrakis Therapeutics, Merck, Inc., Syros Pharmaceuticals, Servier, Mirati Therapeutics, Boehringer Ingelheim, T-Knife Therapeutics, AstraZeneca, Reactive Biosciences, Revolution Medicines, Anji Pharmaceuticals, and Riva Therapeutics; research funding from Mirati Therapeutics, Revolution Medicines, Bristol-Myers Squibb, Novartis, Eli Lilly, Syros Pharmaceuticals, Deerfield Management, and Riva Therapeutics. Michael Needle reports that, at the time this work was done, he was a full-time employee and shareholder in Aveo Oncology. Brian M. Wolpin reports receipt of grant funding to institution from Celgene, Eli Lilly, Novartis, and Revolution Medicine (all unrelated to the present work), and consulting for GRAIL and Mirati. The other authors indicated no financial relationships.